Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT01293669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TC-6987 is a selective nicotinic α-7 receptor ligand (open channel stabilizer) that has demonstrated potent anti-inflammatory/antioxidant properties in animal models. Following the oral administration of a 1mg/kg dose of TC-6987 to diabetic mice (db/db mouse) for 7 weeks, numerous metabolic improvements were observed. Specifically, plasma glucose and triglyceride concentrations declined by approximately 30%; Hb1Ac was reduced by nearly 50%; and TNF-α declined more than 60% relative to control db/db mice Therefore, it appears that TC-6987 could prove beneficial in reducing elevated glucose concentrations in diabetic patients as well as in ameliorating organ damage associated with inflammation, oxidative stress and hyperglycemia.
Study identification
- NCT ID
- NCT01293669
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 440 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2011 (Type not available)
- Primary completion
- Jan 2012 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Sep 13, 2013
2011 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clopton Clinic | Jonesboro | Arkansas | 72401 | — |
| NCA Medical Center | Mountain Home | Arkansas | 72653 | — |
| Associated Pharmaceutical Research Center | Buena Park | California | 90620 | — |
| Cedar Crosse Research Center | Chicago | Illinois | 60607 | — |
| Medex Healthcare Research, Inc | St Louis | Missouri | 63117 | — |
| Om Medical | Henderson | Nevada | 89052 | — |
| MEDEX Healthcare Research, Inc | New York | New York | 10004 | — |
| PMG Research of WS | Winston-Salem | North Carolina | 27103 | — |
| Rapid Medical Research, Inc. | Cleveland | Ohio | 44122 | — |
| Providence Health Partners - Center for Research | Dayton | Ohio | 45439 | — |
| Omega Medical Research | Warwick | Rhode Island | 02888 | — |
| Ellipsis Research | Columbia | South Carolina | 29201 | — |
| PMG Research of Charleston | Mt. Pleasant | South Carolina | 29464 | — |
| New Phase Research and Development | Knoxville | Tennessee | 37923 | — |
| Mercury Clinical Research | Houston | Texas | 77093 | — |
| Quality Research, Inc. | San Antonio | Texas | 78209 | — |
| Highland Clinical Research | Salt Lake City | Utah | 84124 | — |
| Strelitz Diabetes Center, Eastern Virginia Medical School | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01293669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 13, 2013 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01293669 live on ClinicalTrials.gov.